This was confirmed to Prensa Latina by Yanet Borrego, deputy general director and representative of the Cuban vice-presidency of BPL, who added that these trials will be focused on Dermatomyositis and Graft versus Bone.

“We are also transferring the technology of the production process of Cimavax, the vaccine against lung cancer, which already has more than 30 clinical studies at international level,” she said.

In the scientist’s opinion, the joint venture should be ready to begin production and clinical trials in China of this second drug between 2025 and 2026.

“The company is also working on the development of nine innovative products in cooperation with the Cuban side, which are in the research and development phase and should reach the market in about 10 years,” she added.

mh/jav/mem/idm